Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. James Porter, Ph.D., the company's Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco. The presentation will be accessible via live webcast through the Investors section of Nuvalent's website and will remain available for 30 days afterward.
Nuvalent (Nasdaq: NUVL), un'azienda biofarmaceutica in fase clinica che sviluppa terapie mirate per il cancro, ha annunciato la propria partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. James Porter, Ph.D., amministratore delegato dell'azienda, terrà una presentazione martedì 14 gennaio 2025, alle 9:00 PT a San Francisco. La presentazione sarà accessibile tramite webcast dal vivo nella sezione Investitori del sito web di Nuvalent e rimarrà disponibile per 30 giorni dopo.
Nuvalent (Nasdaq: NUVL), una empresa biofarmacéutica en etapa clínica que desarrolla terapias dirigidas contra el cáncer, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. James Porter, Ph.D., el director ejecutivo de la empresa, ofrecerá una presentación el martes 14 de enero de 2025, a las 9:00 a.m. PT en San Francisco. La presentación estará disponible a través de una transmisión en vivo en la sección de Inversores del sitio web de Nuvalent y seguirá estando disponible durante 30 días después.
Nuvalent (Nasdaq: NUVL), 타겟 항암 치료제를 개발 중인 임상 단계의 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 제임스 포터, Ph.D., 회사의 최고 경영자(CEO)는 2025년 1월 14일 화요일, 오전 9시 PT 샌프란시스코에서 발표를 진행할 예정입니다. 발표는 Nuvalent 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트로 연결 가능하며, 이후 30일 동안 시청할 수 있습니다.
Nuvalent (Nasdaq: NUVL), une entreprise biopharmaceutique en phase clinique développant des thérapies ciblées contre le cancer, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé. James Porter, Ph.D., le directeur général de l'entreprise, fera une présentation le mardi 14 janvier 2025, à 9h00 PT à San Francisco. La présentation sera accessible via un webinaire en direct dans la section Investisseurs du site internet de Nuvalent et restera disponible pendant 30 jours après.
Nuvalent (Nasdaq: NUVL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das zielgerichtete Krebstherapien entwickelt, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt gegeben. James Porter, Ph.D., der CEO des Unternehmens, wird am Dienstag, den 14. Januar 2025, um 9:00 Uhr PT in San Francisco eine Präsentation halten. Die Präsentation wird über einen Live-Webcast im Bereich Investoren auf der Website von Nuvalent zugänglich sein und 30 Tage lang verfügbar bleiben.
- None.
- None.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302335786.html
SOURCE Nuvalent, Inc.
FAQ
When is Nuvalent (NUVL) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Nuvalent's (NUVL) J.P. Morgan Healthcare Conference presentation?
What is the focus of Nuvalent's (NUVL) drug development program?
Who will represent Nuvalent (NUVL) at the 2025 J.P. Morgan Healthcare Conference?
